Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Accumulated Expenses (2021 - 2022)

Historic Other Accumulated Expenses for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Q4 2022 value amounting to $1.0 million.

  • Amylyx Pharmaceuticals' Other Accumulated Expenses rose 28953.49% to $1.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.0 million, marking a year-over-year increase of 28953.49%. This contributed to the annual value of $1.0 million for FY2022, which is 28953.49% up from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Other Accumulated Expenses of $1.0 million as of Q4 2022, which was up 28953.49% from $356000.0 recorded in Q3 2022.
  • Over the past 5 years, Amylyx Pharmaceuticals' Other Accumulated Expenses peaked at $1.0 million during Q4 2022, and registered a low of $258000.0 during Q4 2021.